Sun Pharma Advanced Research Co Ltd

Sun Pharma Advanced Research Company Ltd share price softened by 2.03% to Rs 212.85 after the company's net profit witnessed a sharp fall of 101.18% to Rs 20.78 crore, while revenue from operations gained significantly 202.42% to Rs 39.92 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.54 lakh crore, rising 5.16%. It has inched up 0.74% over last one week and advanced by 13.39% in last one month while the market capitalization of Sun Pharma Advanced Research Company Ltd has marginally improved by 2.28% and 27.61% in the same period respectively. Profit before tax (PBT) of Sun Pharma Advanced Research Company Ltd stood at Rs 20.67 crore in Q2 FY26, crashing by 60.10% year-on-year, and tumbling by 101.17% quarter-on-quarter. EBITDA came in at Rs 58 crore, declining 5.82% YoY and plunging by 103.26% sequentially. Total expenses marginally dropped 7.64% to Rs 76.12 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 7.66 crore, soaring by 48.45% YoY, while employee benefits expense was at Rs 29.61 crore, soaring 13.80% YoY. For the TTM ended FY26, revenue from operations sank 45.45% to Rs 39.15 crore, while net profit tumbled by 553.48% to Rs 1553.2 crore, compared to previous TTM. EBITDA saw a sharp decline of 32811% to Rs 1587.81 crore, and PBT plunged by 553.06% to Rs 1553.01 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 238.77 crore in FY26, as against Rs 360.29 crore in FY25. Sun Pharma Advanced Research Company Ltd rallied 45.64% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.63% during the same period.

Sun Pharma Advanced Research Company Ltd will hold a board meeting on August 10, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing with the National Stock Exchange of India Ltd and BSE Limited. The trading window for company shares has been closed for directors, key managerial personnel, designated employees, and connected persons since July 1, 2026, and will remain closed until 48 hours after the financial results are declared and submitted to the stock exchanges.

Sun Pharma Advanced Research Company announced that the 21th Annual General Meeting(AGM) of the company will be held on 10 August 2026.

Sun Pharma Advanced Research Company has allotted 3,85,10,000 warrants to Shanghvi Finance at an issue price of Rs 155.80/- per warrant on preferential basis, out of which the Company has received an amount of Rs 149.99 crore which is equivalent to 25% of the warrant issue price. Each of the Warrant, so allotted, is convertible into or exchangeable for one fully paid-up equity share of face value of Re 1/- of the Company in accordance with the provisions of SEBI ICDR Regulations.

Net profit of Sun Pharma Advanced Research Company reported to Rs 1761.34 crore in the quarter ended March 2026 as against net loss of Rs 59.77 crore during the previous quarter ended March 2025. Sales declined 51.45% to Rs 13.20 crore in the quarter ended March 2026 as against Rs 27.19 crore during the previous quarter ended March 2025. For the full year,net profit reported to Rs 1553.20 crore in the year ended March 2026 as against net loss of Rs 342.51 crore during the previous year ended March 2025. Sales declined 45.45% to Rs 39.15 crore in the year ended March 2026 as against Rs 71.77 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales13.2027.19 -51 39.1571.77 -45 OPM %13433.33-195.59 -4083.68-450.24 - PBDT1763.36-57.72 LP 1575.58-330.39 LP PBT1760.96-60.67 LP 1565.37-342.78 LP NP1761.34-59.77 LP 1553.20-342.51 LP Powered by Capital Market - Live

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 18 May 2026.

Sun Pharma Advanced Research Company (SPARC) has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for US $195 million upon the closing of the transaction. PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby' indicated for the treatment of neonatal seizures. 'The sale of the PRV will enable us to accelerate the development of our pipeline assets and strengthen our external innovation strategy, which has already delivered multiple additions to our portfolio,' said Anil Raghavan, CEO of SPARC. The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Stifel acted as the exclusive financial advisor to SPARC with respect to this transaction.

Sun Pharma Advanced Research Company announced that Dr. Shravanti Bhowmik, Head of Operations Management, and a member of Senior Management Team of the Company has resigned from her position in the Company with effect from the close of business hours on 31 March 2026.

Net Loss of Sun Pharma Advanced Research Company reported to Rs 80.42 crore in the quarter ended December 2025 as against net loss of Rs 79.51 crore during the previous quarter ended December 2024. Sales declined 43.33% to Rs 8.45 crore in the quarter ended December 2025 as against Rs 14.91 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales8.4514.91 -43 OPM %-670.30-494.23 - PBDT-65.42-76.30 14 PBT-67.99-79.44 14 NP-80.42-79.51 -1 Powered by Capital Market - Live

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live